======= PHF8 =======
== Gene Information ==
* **Official Symbol**: PHF8
* **Official Name**: PHD finger protein 8
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=23133|23133]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9UPP1|Q9UPP1]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=PHF8&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PHF8|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/300560|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: The protein encoded by this gene is a histone lysine demethylase that preferentially acts on histones in the monomethyl or dimethyl states. The encoded protein requires Fe(2+) ion, 2-oxoglutarate, and oxygen for its catalytic activity. The protein has an N-terminal PHD finger and a central Jumonji C domain. This gene is thought to function as a transcription activator. Defects in this gene are a cause of syndromic X-linked Siderius type intellectual disability (MRXSSD) and over-expression of this gene is associated with several forms of cancer. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2017].
* **UniProt Summary**: N/A
|JmjC|
|PHD|
|histone H4-K20 demethylation|
|negative regulation of chromatin silencing at rDNA|
|histone demethylase activity (H4-K20 specific)|
|regulation of chromatin silencing at rDNA|
|histone demethylase activity (H3-K27 specific)|
|histone H3-K27 demethylation|
|histone H3-K36 demethylation|
|histone demethylase activity (H3-K36 specific)|
|histone demethylase activity (H3-K9 specific)|
|histone demethylase activity|
|histone H3-K9 demethylation|
|2-oxoglutarate-dependent dioxygenase activity|
|negative regulation of chromatin silencing|
|positive regulation of transcription by RNA polymerase I|
|histone lysine demethylation|
|histone demethylation|
|protein dealkylation|
|protein demethylation|
|regulation of transcription by RNA polymerase I|
|negative regulation of gene silencing|
|regulation of chromatin silencing|
|negative regulation of chromatin organization|
|methylated histone binding|
|positive regulation of gene expression, epigenetic|
|demethylation|
|G1/S transition of mitotic cell cycle|
|cell cycle G1/S phase transition|
|regulation of gene silencing|
|iron ion binding|
|negative regulation of chromosome organization|
|regulation of chromatin organization|
|regulation of gene expression, epigenetic|
|nuclear membrane|
|mitotic cell cycle phase transition|
|cell cycle phase transition|
|regulation of chromosome organization|
|histone modification|
|negative regulation of organelle organization|
|covalent chromatin modification|
|chromatin binding|
|mitotic cell cycle process|
|mitotic cell cycle|
|chromatin organization|
|negative regulation of cellular component organization|
|brain development|
|head development|
|zinc ion binding|
|nucleolus|
|oxidation-reduction process|
|central nervous system development|
|cell cycle process|
|chromosome organization|
|regulation of organelle organization|
|cell cycle|
|positive regulation of transcription, DNA-templated|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|positive regulation of RNA metabolic process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-2.46|
|[[:results:exp229|Dimethyloxaloylglycine 100μM R05 exp229]]|-2.04|
|[[:results:exp184|Ixabepilone 0.004 to 0.005μM on day4 R04 exp184]]|-1.98|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|-1.96|
|[[:results:exp89|Vemurafenib 6.6μM R02 exp89]]|-1.95|
|[[:results:exp67|BVD-523 15μM R02 exp67]]|-1.83|
|[[:results:exp35|TRAIL 5ng/ml R00 exp35]]|-1.78|
|[[:results:exp354|Diepoxybutane 3μM R07 exp354]]|-1.77|
|[[:results:exp288|HMS-I2 10μM R06 exp288]]|1.7|
|[[:results:exp531|THZ1 0.06μM R08 exp531]]|1.73|
|[[:results:exp301|VER-155008 3.9μM R06 exp301]]|1.79|
|[[:results:exp318|ABT-702 5μM R07 exp318]]|1.97|
|[[:results:exp439|QNZ 0.01μM R08 exp439]]|2.2|
^Gene^Correlation^
|[[:human genes:h:hgc6.3|HGC6.3]]|0.46|
|[[:human genes:u:ube2q1|UBE2Q1]]|0.426|
Global Fraction of Cell Lines Where Essential: 0/683
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/26|
|bone|0/25|
|breast|0/30|
|central nervous system|0/49|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/11|
|fibroblast|0/1|
|gastric|0/14|
|kidney|0/18|
|liver|0/19|
|lung|0/72|
|lymphocyte|0/14|
|ovary|0/25|
|pancreas|0/22|
|peripheral nervous system|0/15|
|plasma cell|0/12|
|prostate|0/1|
|skin|0/20|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/28|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 10263
* **Expression level (log2 read counts)**: 5.99
{{:chemogenomics:nalm6 dist.png?nolink |}}